Screening for anti-methicillin resistant Staphylococcus aureus (MRSA) bacteriocin producing bacteria

African Journal of Biotechnology

Volumn 8, Issue 3, 2009, Pages 365-368

  Nawaz, Syed Kashif ^a   Riaz, Samreen ^a   Riaz, Saba ^a   Hasnain, Shahida ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

Anti MRSA; Bacteriocins; Infection treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; BACTERIOCIN; CEFRADINE; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; IMEPENUM; OXACILLIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ISOLATION; DRUG SCREENING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 60549105215     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Brooks GF. Butel JS. Morse SA (1998). Jawetz. Melnick. and Adelberg's Medical Microbiology. Appleton & Lange a Simon & Schuster Company. Princeton Hall. Upper Saddle River. New Jersey. USA. p. 269
2. Cheesbrough M (2001). District Laboratory Practice in Tropical Countries. Part 2. Cambridge University Press. Cambridge.
3. Cosgrove SE. Sakoulas G. Perencevich EN. Perencevich EN. Schwaber MJ. Karchmer AW. Carmeli Y (2003). Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 36: 53-59.
4. Cottagnoud P (2008). Daptomycin: a new treatment for insidious infections due to gram-positive pathogens. Swiss Med Wkly. 138(7-8):93-99.
5. De Man JD. Rogosa M. Sharpe ME (1960). A medium for the cultivation of lactobacilli. J. Appl. Bact. 23: 130-135.
6. de Vrese M. Winkler P. Rautenberg P. Harder T. Noah C. Laue C. Ott S. Hampe J. Schreiber S (2005). other authors. Effect of Lactobacillus gasseri PA 16/8. Bifidobacterium longum SP 07/3. B. bifidum MF 20/5 on common cold episodes: a double blind. randomized. controlled trial. Clin Nutr. 24: 481 -491.
7. Engemann JJ. Carmeli Y. Cosgrove SE. Fowler VG. Bronstein MZ. Trivette SL. Briggs JP. Sexton DJ. Kaye KS (2003). Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 36: 592-598.
8. European Commission (2005). Opinion of the FEEDAP Panel on the updating of the criteria used in the assessment of bacteria for resistance to antibiotics of human or veterinary importance. EFSA J. 223: 1-12.
9. Graffunder EM. Venezia RA (2002). Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother. 49: 999-1005.
10. Hanaki H. Hiramatsu K (1997). Emerging infectious and drug-resistant diseases - vancomycin resistant gram-positive cocci. Nippon Naika Gakkai Zasshi. 86(11): 2075-2080.
11. Hiramatsu K. Hanaki H. Ino T. Yabuta K. Oguri T. Tenover FC (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob Chemother. 40(1):135-136.
12. Isolauri E. Juntunen M. Rautanen T. Sillanaukee P. Koivula T (1991). A human Lactobacillus strain (Lactobacillus casei sp. strain GG) promotes recovery from acute diarrhea in children. Pediatrics 88: 90-97.
13. Johnson AP. Pearson A. Duckworth G (2005). Surveillance and epidemiology of MRSA bacteraemia in the UK. J. Antimicrob. Chemother. 56: 455-462.
14. Kalliomaki M. Salminen S. Arvilommi H. Kero P. Koskinen P. Isolauri E (2001). Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357: 1076-1079.
15. Kalmokoff ML. Bartlett F. Teather RM (1996). Are Ruminal Bacteria Armed with Bacteriocins? J. Dairy Sci. 79: 2297-2306.
16. Klein G. Pack A. Bonaparte1 C. Reuter G (1998). Taxonomy and physiology of probiotic lactic acid bacteria. Int J. Food Microbiol. 41:103-125.
17. Lowy FD (1998). Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
18. Nair PS Surendran PK (2005). Biochemical characterization of lactic acid bacteria isolated from fish and prawn. J. Cult. Col. 4: 48-52.
19. Nash DR. Harman J. Wald ER. Kelleher KJ (2002). Antibiotic prescribing by primary care physicians for children with upper respiratory tract infections. Arch. Pediatr. Adolesc Med. 156: 1114-1119.
20. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. In NCCLS approved standard M100-S14.2004.NCCLS. Wayne. PA USA.
21. Noskin GA Rubin RJ. Schentag JJ. Kluytmans J. Hedblom EC. Smulders M. Lapetina E. Gemmen E (2005). The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch. Int. Med. 165: 1756-1761.
22. Oliveira DC. Tomasz A. de Lencastre H (2002). Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus. Lancet Infect. Dis. 2(3):180-189.
23. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK. (2005). other authors. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 128: 541-551
24. Riley MA, Wertz JE (2002). BACTERIOCINS: Evolution, Ecology, and Application. Ann. Rev. Microbiol. 56: 117-137.
25. Schillinger U, Lücke KF (1989). Antibacterial activity of Lactobacillus sake isolated from meat. Appl. Environ. Microbiol. 55: 1901-1906.
26. Settanni L, Corsetti A (2008). Application of bacteriocins in vegetable food biopreservation. Int. J. Food Microbiol. 121 (2): 123-138.
27. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson- Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR (1999). Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med. 340(7): 493-501.